Zenas BioPharma, Inc. Common Stock (ZBIO) — Cash Flow-to-Debt Ratio
Zenas BioPharma, Inc. Common Stock (ZBIO) has a Cash Flow-to-Debt Ratio of -0.13x as of June 2026, meaning its operating cash flow of $-57.24 Million could theoretically repay 0% of its total liabilities ($454.59 Million) in one year. See Zenas BioPharma, Inc. Common Stock leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Zenas BioPharma, Inc. Common Stock Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for Zenas BioPharma, Inc. Common Stock across 4 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Zenas BioPharma, Inc. Common Stock.
Annual Cash Flow-to-Debt Ratio for Zenas BioPharma, Inc. Common Stock (2022–2025)
Year-by-year debt coverage analysis for Zenas BioPharma, Inc. Common Stock. Check earnings quality score of Zenas BioPharma, Inc. Common Stock to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.22x | $-172.33 Million | $141.50 Million | ▲ +41.5% |
| 2024 | -2.08x | $-119.67 Million | $57.51 Million | ▼ -1903.3% |
| 2023 | -0.10x | $-30.53 Million | $293.90 Million | ▲ +57.8% |
| 2022 | -0.25x | $-65.65 Million | $266.87 Million | — |